Cumberland Pharmaceuticals' Q3 revenue declines to $8.3 mln

Reuters

Nov 05, 2025

Cumberland Pharmaceuticals' Q3 revenue declines to $8.3 mln

Overview

Cumberland Q3 2025 revenue was $8.3 mln, reflecting a decline from last year
Company reports Q3 net loss of $1.9 mln
Cumberland partners with RedHill to commercialize Talicia, expanding product portfolio

Outlook

Company did not provide specific financial guidance for future quarters

Result Drivers

PRODUCT PORTFOLIO GROWTH - 12% year-to-date revenue growth attributed to FDA-approved product portfolio

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Revenue		$8.30 mln
Q3 Adjusted EPS		-$0.06
Q3 Net Income		-$1.9 mln
Q3 Operating Expenses		$10.3 mln

Analyst Coverage

The one available analyst rating on the shares is "hold"
The average consensus recommendation for the pharmaceuticals peer group is "buy."

Press Release: ID:nPnb9ThCHa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2581760096"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581760096\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581760096?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 06:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581760096","market":"fut","top_or_hot":-1,"title":"Cumberland Pharmaceuticals' Q3 revenue declines to $8.3 mln","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Cumberland Pharmaceuticals' Q3 revenue declines to $8.3 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Cumberland Q3 2025 revenue was $8.3 mln, reflecting a decline from last year</p></li><li><p>Company reports Q3 net loss of $1.9 mln</p></li><li><p>Cumberland partners with RedHill to commercialize Talicia, expanding product portfolio</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company did not provide specific financial guidance for future quarters</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>PRODUCT PORTFOLIO GROWTH - 12% year-to-date revenue growth attributed to FDA-approved product portfolio</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td></td><td><p>$8.30 mln</p></td><td></td></tr><tr><td><p>Q3 Adjusted EPS</p></td><td></td><td><p>-$0.06</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$1.9 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$10.3 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The one available analyst rating on the shares is \"hold\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy.\"</p></li></ul><p>Press Release: <span>ID:nPnb9ThCHa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cumberland Pharmaceuticals' Q3 revenue declines to $8.3 mln</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCumberland Pharmaceuticals' Q3 revenue declines to $8.3 mln\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-05 06:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Cumberland Pharmaceuticals' Q3 revenue declines to $8.3 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Cumberland Q3 2025 revenue was $8.3 mln, reflecting a decline from last year</p></li><li><p>Company reports Q3 net loss of $1.9 mln</p></li><li><p>Cumberland partners with RedHill to commercialize Talicia, expanding product portfolio</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company did not provide specific financial guidance for future quarters</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>PRODUCT PORTFOLIO GROWTH - 12% year-to-date revenue growth attributed to FDA-approved product portfolio</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td></td><td><p>$8.30 mln</p></td><td></td></tr><tr><td><p>Q3 Adjusted EPS</p></td><td></td><td><p>-$0.06</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$1.9 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$10.3 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The one available analyst rating on the shares is \"hold\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy.\"</p></li></ul><p>Press Release: <span>ID:nPnb9ThCHa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nL1N3WG1L4:1","article_id":"2581760096","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581760096","pubTimestamp":1762294281,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cumberland Pharmaceuticals' Q3 revenue declines to $8.3 mlnOverviewCumberland Q3 2025 revenue was $8.3 mln, reflecting a decline from last yearCompany reports Q3 net loss of $1.9 mlnCumberland partner","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4557":"大麻股","CPIX":"坎伯兰药业"},"translate_title":"Cumberland Pharmaceuticals第三季度收入下降至830万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CPIX":0.9},"content_text":"Cumberland Pharmaceuticals' Q3 revenue declines to $8.3 mlnOverviewCumberland Q3 2025 revenue was $8.3 mln, reflecting a decline from last yearCompany reports Q3 net loss of $1.9 mlnCumberland partners with RedHill to commercialize Talicia, expanding product portfolioOutlookCompany did not provide specific financial guidance for future quartersResult DriversPRODUCT PORTFOLIO GROWTH - 12% year-to-date revenue growth attributed to FDA-approved product portfolioKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Revenue$8.30 mlnQ3 Adjusted EPS-$0.06Q3 Net Income-$1.9 mlnQ3 Operating Expenses$10.3 mlnAnalyst CoverageThe one available analyst rating on the shares is \"hold\"The average consensus recommendation for the pharmaceuticals peer group is \"buy.\"Press Release: ID:nPnb9ThCHaFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}